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As a facultative intracellular pathogen, Staphylococcus aureus invades macrophages and then promotes the cytoprotection of
infected cells thus stabilizing safe niche for silent persistence.is process occurs through the upregulation of crucial antiapoptotic
genes, in particular, myeloid cell leukemia-1 (MCL-1). Here, we investigated the underlying mechanism and signal transduction
pathways leading to increased MCL-1 expression in infected macrophages. Live S. aureus not only stimulated de novo synthesis
of Mcl-1, but also prolonged the stability of this antiapoptotic protein. Consistent with this, we proved a crucial role of Mcl-1
in S. aureus-induced cytoprotection, since silencing of MCL1 by siRNA profoundly reversed the cytoprotection of infected cells
leading to apoptosis. IncreasedMCL1 expression in infected cells was associated with enhanced NF𝜅𝜅B activation and subsequent
IL-6 secretion, since the inhibition of both NF𝜅𝜅B and IL-6 signalling pathways abrogated Mcl-1 induction and cytoprotection.
Finally, we con�rmed our observation in vivo in murine model of septic arthritis showing the association between the severity
of arthritis and Mcl-1 expression. erefore, we propose that S. aureus is hijacking the Mcl-1-dependent inhibition of apoptosis
to prevent the elimination of infected host cells, thus allowing the intracellular persistence of the pathogen, its dissemination by
infected macrophages, and the progression of staphylococci diseases.
1. Introduction
Staphylococcus aureus is a major cause of community-
acquired and nosocomial infections, including localised and
systemic life-threatening conditions, such as osteomyelitis,
endocarditis, pneumonia, and septicaemia [1]. Despite the
increasing morbidity and mortality due to staphylococcal
infections, relatively little is known about the molecular
mechanisms by which this pathogen disseminates system-
ically. Recent studies have shown that S. aureus not only
survives phagocytosis by neutrophils and macrophages but
is also able to persist inside these cells [2, 3]. As is the case
for Listeria monocytogenes and Mycobacterium tuberculosis
[4–6], long-term survival, especially inside macrophages,
may be a mechanism of dissemination of staphylococci.
is hypothesis is further supported by the observation
that intracellular S. aureus manipulates macrophage cell
signalling processes and transcription to promote survival
of infected phagocytes without bacterial eradication [7].
erefore, precise elucidation of the mechanism of induction
of cytoprotection in macrophages, a potential vehicle for
pathogen spreading in the host, is of high importance.
Recently, we showed that live intracellular bacteria induce
cytoprotection in human and murine macrophages, allowing
the pathogen to silently persist and remain invisible to the
immune system [3, 7]. We proposed that the pathogen
induces a prosurvival signalling pathway through the induc-
tion of expression of antiapoptotic factors, including myeloid
cell leukemia-1 (Mcl-1), an antiapoptotic protein of the Bcl-2
family. Mcl-1 possesses BCL-2 homology (BH) domains 1–4,
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similar to other antiapoptotic BCL-2 family members (BCL-
2, BCL-XL, BCL-W, and A1). It inhibits cell death by seques-
tering proapoptotic proteins (e.g., BAX, BAK, BIM, PUMA,
and BAD), thus stabilising the mitochondrial membrane and
preventing release of cytochrome c [8, 9]. MCL1 expression
can be induced by survival and differentiation signals such
as cytokines and growth factors produced as a result of
activation of a number of well-known signal transduction
pathways (e.g., MAP kinases, PI3K/Akt, JAK/STAT, and
NF𝜅𝜅B) [10]. Cellular levels of Mcl-1 are regulated also by
alteration of this protein turnover rate, which is dependent
on PEST sequences within the N-terminal region of Mcl-1
and other motifs that target the protein for degradation by
the proteasome [8].
In the current paper, we documented the elevated level
of Mcl-1 in S. aureus-infected human primary macrophages
and joints inmurinemodel of septic arthritis, associated with
in�ltration of macrophages into the synovia. We showed for
the �rst time that small inhibitory (si)RNA silencing ofMCL1
in S. aureus-infected macrophages abrogates cytoprotection
against staurosporine-induced apoptosis, con�rming the role
of Mcl-1 in sustaining the viability of macrophages during
infection. Furthermore, we established that S. aureus induced
Mcl-1 through signalling pathways that required NF𝜅𝜅B and
IL-6, since inhibition of these pathways partly suppressed
bacterial-mediated enhancement of Mcl-1 expression and
cytoprotection. erefore, we propose a model in which
expression of prosurvival genes, such asMCL1, enables viru-
lent S. aureus strains to circumvent cell death, thus ensuring
a safe ecological niche prior to dissemination. Regulation
of human macrophage longevity by intracellular S. aureus
has clinical relevance for understanding the pathogenesis of
Staphylococci-caused infectious diseases.
2. Materials andMethods
2.1. Cell Culture. PBMCs were isolated from human blood
using a Lymphocyte Separation Medium (PAA) density
gradient yielding the fraction highly enriched in monocytes
(90% CD14-positive) as described previously [7]. Cells were
plated at 3×106/well in 24-well plates (Sarstedt) in RPMI1640
(PAA) supplementedwith 2mML-glutamine, 50 𝜇𝜇g/mL gen-
tamicin (Sigma), and 10% autological human serum. Aer
24 h, nonadherent PBMCs were removed by washing with
complete medium, and adherent cells were differentiated
to hMDMs in this medium for 7 days with fresh medium
changed every 2 days. Blood was obtained from the Red
Cross, Krakow, Poland. e Red Cross de-identi�ed blood
materials as appropriate for human subjects con�dentiality
assurance. us, the current paper adheres to appropri-
ate exclusions from human subjects approval. e murine
macrophage cell line RAW 264.7 obtained from American
Type Culture Collection was maintained in DMEM (PAA)
supplemented with 5% fetal bovine serum.
2.2. Bacterial Strains, Storage, and Growth Conditions. e
laboratory S. aureus strain Newman was kindly provided by
Dr. T. Foster (Trinity College, Dublin, Ireland) and E. coli
strain was from laboratory stocks. Bacteria were grown to
the stationary growth phase at 37∘Covernight under constant
rotation (180 rpm), then were collected by centrifugation
(5,000×g, 8min), washed with phosphate-buffered saline,
and resuspended in PBS to the desired OD600 nm. Staphylo-
cocci were opsonized by incubation at 37∘C for 30min in heat
inactivated FCS, washed, and resuspended in PBS. Numbers
of vital bacteria in samples used in phagocytosis assay were
routinely veri�ed by plating dilutions on agar plates and
counting colonies to determine CFU per mL. Heat treatment
(80∘C for one hour) was used to kill bacteria.
2.3. Macrophages Infection. Macrophage infection was per-
formed using S. aureus and E. coli as described previously
[7]. Unspeci�c cell activation by phagocytosis of inert par-
ticles was determined using latex beads (1.1𝜇𝜇m; Sigma) as
described previously [7]. Phagocytosis assays were carried
out for 2 hours at 37∘C at a multiplicity of infection (MOI)
of 1 : 50 (hMDMs) or 1 : 5 (RAW 264.7), resulting in >85% of
macrophages engul�ng at least one bacterium.Aer that time
cells were rinsed 4 times with ice-cold phosphate-buffered
saline. Any remaining nonphagocytosed bacteria were killed
by culturing in medium containing gentamicin (50 𝜇𝜇g/mL)
for 24 h. e medium was then replaced with fresh media
without antibiotics, and cultures were maintained for the
desired time. Cells treated identically, but without bacteria,
were analyzed in all experiments as a control (mock-infected
cells).
For inhibitor experiments, before inoculation with bac-
teria or applying control stimulus, macrophages were prein-
cubated for 30min with nontoxic doses (data not shown) of
theNF𝜅𝜅B inhibitor Bay 11-7082 (2–40 𝜇𝜇M).Where indicated,
cycloheximide (a �nal concentration 10 𝜇𝜇g/mL) was added
30min before infection with bacteria and present in media
until cells were washed 30min aer infection.is treatment
reduced de novo translation of proteins in macrophage by
95.5% as determined by 35S-Met incorporation (data not
shown).
2.4. Viability Assays. Aer S. aureus phagocytosis and/or
treatment with compounds inducing apoptosis, macrophage
viability was examined by lactate dehydrogenase (LDH)
release. e LDH release assay was performed using a Cyto-
Tox96 Non-Radioactive Lactate Dehydrogenase Cytotoxicity
Assay kit (Promega). Infected and control hMDMs or RAW
264.7 cells in a 24-well tissue culture plate (3 × 105 cells
per well) were treated with 1 𝜇𝜇M staurosporine (STS; Sigma)
added 2 h or 24 h aer-infection as a stimulator of apoptosis.
Samples were then incubated for 6 h or 24 h, and 200 𝜇𝜇L of
culture medium were withdrawn and subjected to analysis as
described previously [7].
2.5. Analysis of Caspase-3 Activity. e activity of caspase-
3 was determined by release of 7-amino-4-tri�uoromethyl-
coumarin (AFC) from aDEVD-AFC peptide substrate. Cells,
both control and exposed to S. aureus, with or without
apoptotic stimuli, were collected by centrifugation (200×g,
5min, 4∘C), washed with ice-cold PBS, and resuspended
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in 100 𝜇𝜇L of lysis buffer (50mM Tris, pH 7.5, 150mM
NaCl, 1% NP-40, 0.5% deoxycholic acid, and 0.1% SDS).
Samples were then incubated on ice for 20min and subjected
to centrifugation (16,000×g, 10min). e protein content
of supernatants was measured using a BCA method, and
caspase activity was determined by using a Spectra Max
Gemini EM (Molecular Devices) as described previously
[7].
2.6. Protein Isolation and Immunoblotting. Whole cellular
extracts from control and stimulated cells were prepared
using 100𝜇𝜇L of RIPA-lysis buffer (0.25% Na-deoxycholate,
0.5% Nonidet P-40, 0.05% SDS, protease inhibitor cocktail,
and 2.5mM EDTA in PBS) and stored at −20∘C. e joints
of DBA1 mice were homogenized in 300 𝜇𝜇L of RIPA-lysis
buffer. Equal amounts of protein (40 𝜇𝜇g/well) were sepa-
rated using SDS-PAGE (12% or 16% gels depending on
molecular mass of proteins of interest) and electrotransferred
onto nitrocellulose membranes (BioRad) in buffer composed
of 25mM Tris, 0.2M glycine, and 20% methanol (30V,
overnight). Nonspeci�c binding sites were blocked with 3%
BSA in TTBS buffer (20mM Tris, 0.5M NaCl, and pH
7.5 with 0.05% Tween 20) for 1 h, followed by 1-2-hour
incubation with the relevant primary antibody: 100-fold
diluted anti-Mcl-1 (Santa Cruz), or 3,000-fold diluted anti-𝛽𝛽-
actin (Sigma). Membranes were washed extensively in TTBS
buffer and incubatedwith secondary horseradish peroxidase-
(HRP-) conjugated antibodies, 10,000-fold diluted donkey
anti-rabbit IgG, or 20,000-fold diluted sheep anti-mouse IgG,
for 1 h in TTBS buffer containing 1% BSA. Membranes were
washed (4×15min) in TTBS buffer, and blots were developed
using ECL detection (Western Blotting Detection Reagents;
Amersham Biosciences).
2.7. Densitometric Analyses. Densitometric analyses of west-
ern blots were performed using Kodak Digital Soware.
Results are presented as mean values of arbitrary densitomet-
ric units corrected for background intensity or as the fold of
increase over a level characteristic for nonstimulated cells.
2.8. Quantitative PCR (qRT-PCR). Total cellular RNA was
extracted from cultured hMDMs using aRNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions. RNA
samples were DNase treated, and cDNA was prepared by
reverse transcription using RevertAidTM First Strand cDNA
Synthesis Kit (Fermentas). Five hundred nanograms of RNA
from each sample were used for cDNA synthesis reaction
with oligo(dT) primers according to the manufacturer’s
instructions. Quantitative PCR reaction was performed with
an SYBR Green method in a reaction volume of 20𝜇𝜇L,
containing 1 𝜇𝜇L of cDNA sample, 0.5 𝜇𝜇M of each primer,
and 1x SYBR Green JumpStart Taq Ready Mix (Sigma).
qRT-PCR forward and reverse primers for IL-6, MCL1, and
MCL1S genes and for the housekeeping EF-2 gene (used for
normalization) are listed in Table 1. Aer 5min of initial
denaturation at 95∘C, reactions were carried out for 40 cycles
at the given conditions: denaturation, 95∘C, 20 sec; annealing,
56∘C–62∘C (as shown in Table 1), 60 sec; extension, 72∘C,
60 sec; followed by a �nal elongation step at 72∘C for 10min.
All the reactions were performed in duplicates. Means for
threshold cycle (Ct) values were calculated and analyzed
using the �delta-delta Ct� quanti�cation method [11]. Rou-
tinely, for the evaluation of quality of qRT-PCR reactions,
samples were resolved on nondenaturing 1.5% agarose gels
and visualized by staining with ethidium bromide.
2.9. Cytokine Assay. Two hundred 𝜇𝜇L of cell culture super-
natants were collected and stored at −80∘C until analysis.e
level of IL-6 was determined by using commercially available
ELISA kits according to the manufacturer’s instructions
(R&D Systems).
2.10. Transfection with siRNA. Silencing of the MCL1 gene
expression was accomplished by transfection of cells with
speci�c siRNA or with negative control siRNA (Accell Smart
pool and Control pool, resp.,ermo Scienti�c Dharmacon).
Brie�y, for each of transfected wells, siRNA (�nal concentra-
tion 60 nM) was combined with 3 𝜇𝜇L of lipofectamine 2000
(Invitrogen) in Opti-MEM medium (Invitrogen). Transfec-
tion was performed for 4 h followed by 24 h of normal cell
growth before desired assays were performed.
2.11. Evaluation of NF𝜅𝜅B Activity. NF𝜅𝜅B activity was mea-
sured in nuclear protein extracts by the EMSA method.
Nuclear extracts were prepared by a miniextraction proce-
dure as described before [12]. e protein concentration
was measured with bicinchoninic acid (BCA method), and
the obtained extracts were frozen (−80∘C) in 10% glycerol.
For the NF-𝜅𝜅B-directed EMSA, double-stranded probes were
prepared using the pair of primersAGCTTCAGAGGGGAC-
TTTCCGAGAGG and AGTCTCCCCTGAAAGGCTCTC-
CTCGA. EMSA was performed as described before [12].
2.12. Septic Arthritis Induction and Examination of Infection.
Male DBA1 mice (8–12 weeks old) were obtained from the
breeding unit of the Department of Human Developmental
Biology, Jagiellonian University, School of Medicine. Mice
were fed autoclaved food and water. All experiments were
conducted according to guidelines of the Animal Use and
Care Committee of the Jagiellonian University School of
Medicine. Mice were inoculated with S. aureus in the tail
vein (5 × 107 in 200 𝜇𝜇L) at day 0. e overall condition
was evaluated by assessment of body weight and general
appearance. e hind paws and forepaws were inspected
every second day. Animals were observed daily for the
presence of arthritis, and the clinical severity of disease was
scored for each paw on a scale of 0–4, with the index being the
sumof the scores for all four paws.e criteria for the grading
were as follows: 0: no evidence of erythema and swelling;
1: mild erythema and swelling of the wrist or the ankle;
2: moderate erythema and swelling from the wrist to the
metacarpal joints or from the ankle to the metatarsal joints;
3: severe erythema and swelling of the entire paw including
digits; 4: maximal erythema and swelling of the paw. e
bacterial load in joints, kidney, and spleen was examined at
time of sacri�ce (8 day p.i.). e organ homogenates were
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T 1: Oligonucleotide sequences used in qRT-PCR.
Oligonucleotide Annealing (∘C) Sequence
EF-2 F 62 5′-GACATCACCAAGGGTGTGCAG-3′
EF-2 R 62 5′-TCAGCACACTGGCATAGAGGC-3′
IL-6 F 54 5′-CATCTTTGGAAGGTTCAGGTTTGT-3′
IL-6 R 54 5′-AGCCCTGAGAAAGGAGACATGTA-3′
MCL1 F 62 5′-TAAGGACAAAACGGGACTGG-3′
MCL1 R 62 5′-ACCAGCTCCTACTCCAGCAA-3′
MCL1S F 62 5′-GCAACCACGAGACGGCC-3′
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F 1: Mcl-1 expression is induced speci�cally by S. aureus phagocytosis and is dependent on bacterial dose and viability. (a) e effect
of phagocytosis of S. aureus (Sa), E. coli (Ec), and latex beads (LTX) onMcl-1 protein levels was assessed by immunoblot. Aer phagocytosis,
cells were cultured for 8 h and then protein fractions were prepared as described in Section 2. Representative immunoblot from three separate
experiments performed on hMDMs derived from different donors is shown. Mcl-1 was visualised by immunoblot using anti-Mcl-1-speci�c
antibodies. (b) e effect of S. aureus phagocytosis on Mcl-1 levels is proportional to an infection dose. A representative immunoblot from
three separate experiments performed on hMDMs derived from different donors is shown. (c)e effect of phagocytosis of live (Sa) and dead,
heat-killed S. aureus (Sa HI) onMCL1 expression was determined by qRT-PCR. Data are from independent reactions using hMDMs derived
from different donors. Paired points represent the response of hMDMs obtained from the same donors to both live and dead bacteria. Bars
represent relative means ± SD. ∗∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃� �S: not signi�cant. (d)e comparison of expression levels of proapoptoticMCL1S (white bars)
versus antiapoptoticMCL1 (�lled bars). Results were obtained by qRT-PCR from three separate experiments. ∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
plated on tryptic soy agar and CFU counted aer overnight
incubation at 37∘C.
2.13. Statistics. Results were analy�ed for statistical signi�-
cance using the nonparametric Student’s 𝑡𝑡-test. Differences
were considered signi�cant when 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
3. Results
3.1. S. aureus Speci�call� ���uces Mcl�1 E�pressio� i� �u�a�
Macrophages. We previously showed that S. aureus can
protect infected macrophages against apoptosis through
upregulation of expression of antiapoptotic genes [7]. Among
these genes, MCL1 plays a key role in macrophage survival
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F 2: S. aureus increases both de novoMcl-1 synthesis and stability. (a) Time course ofMCL1 expression in control and S. aureus-infected
macrophages (hours aer-infection; p.i.) was monitored by qRT-PCR, as described in Section 2. Data represent the mean values calculated
from the results of three independent experiments using hMDMs derived from different donors. Bars represent mean relative expression ±
SD. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃; ∗∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃. (b, c) Time course of Mcl-1 protein synthesis following S. aureus infection. Mcl-1 levels were measured at
different time points between 0.5 and 20 h p.i. by immunoblot. (b) Representative immunoblot from three separate experiments performed
on macrophages derived from different donors. (c) Relative Mcl-1 levels obtained by densitometric analyses of western blots. Results from
three separate experiments. Data represent means ± SD. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃; ∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃; ∗∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃. (d) Mcl-1 stability in macrophages incubated
in the presence of cycloheximide (CHX) (10 𝜇𝜇g/mL) in the absence (circles) or presence (squares) of S. aureus (MOI 1 : 50). At time periods
of up to 3 h, Mcl-1 levels were detected by immunoblot in cell lysates. Data represents Mcl-1 levels relative to time 0, which was arbitrarily set
as 100%, obtained by densitometric analyses of western blots. Data represent means ± SD of three separate experiments. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
[13, 14]. Here, we investigated potential mechanisms of Mcl-
1 regulation, as well as its role in cytoprotection induced by
S. aureus.eMcl-1 induction in response to phagocytosis of
different bacteria and particles was examined by incubating
macrophages with S. aureus, E. coli, or latex beads for 8 h. S.
aureus induced the highest level of Mcl-1, about �ve-times
more (4𝑃78 ± 𝑃𝑃96-fold above the control level) than that seen
in mock-infected cells (Figure 1(a)). By contrast, no change
inMcl-1 levels was observed aer incubationwith latex beads
(𝑃𝑃𝑃6 ± 𝑃𝑃𝑃6) and only a slight upshi aerE. coli (𝑃𝑃78 ± 𝑃𝑃63)
(Figure 1(a)). e enhanced Mcl-1 production in response
to S. aureus was proportional to infection rate (Figure 1(b))
and was exerted only by viable bacterial cells (Figure 1(c)).
e latter was clearly apparent from a comparison of relative
levels of MCL1 mRNA induced in response to live or dead
bacteria in macrophages derived from different blood donors
(8.87 versus 2.75, 4.36 versus 2.35, and 2.24 versus 0.4,
resp.). An intriguing feature of S. aureus-induced Mcl-1
expression was the synthesis of an alternatively splicedMCL1
gene product (MCL1S proapoptotic isoform), which was
observed at the mRNA level early aer infection (Figure
1(d)). Signi�cantly, however, the expression ofMCL1S was at
much lower level compared to the full-length, antiapoptotic
MCL1 form (Figure 1(d)).
































F 3: Exposure to S. aureus triggers Mcl-1 production in vivo. (a) Immunoblot reveals increase in Mcl-1 expression in in�amed joints
derived from three individual S. aureus-infected mice (Sa) in comparison to noninfected animals (Veh.). A representative immunoblot from
three separate experiments is shown. (b) e expression of Mcl-1 in joints correlates with infection score and bacterial load determined as
described in Section 2. Data represents Mcl-1 levels in noninfected (Veh.; 𝑛𝑛 𝑛 𝑛) and S. aureus-infected (Sa; 𝑛𝑛 𝑛 𝑛) animals, obtained by
densitometric analyses of western blots.
Taken together, these results suggested that stimulation of
Mcl-1 expression inmacrophages is preferentially induced by
viable S. aureus.
3.�. S. aureus In�uences Mcl-1 Synthesis and �urnover �ate.
To correlate S. aureus-induced cytoprotection with the
expression of MCL1, we determined the time dependence
of the induction of speci�c mRNA aer macrophage chal-
lenge with bacteria. A 4-fold increase of MCL1 mRNA was
observed 1 h aer-infection, with sustained upregulation
observed for up to 6 h (Figure 2(a)). At the protein level,
Mcl-1 levels were signi�cantly increased 2 h aer-infection,
reached a maximum at 8 h, and remained at 3-fold higher
levels compared to mock-infected cells for at least 20 h
(Figures 2(b) and 2(c)).
Since the observed high levels of expression ofMcl-1 in S.
aureus-infected macrophages could be the result of either de
novo synthesis or the decreased turnover rate, we compared
Mcl-1 stability inmacrophages treated with cycloheximide in
the absence and presence of S. aureus. As shown in Figure
2(d), in mock-infected cells, blocking de novo biosynthesis
resulted in a rapid decrease in the cellular levels of Mcl-1. By
contrast, in cells infectedwith S. aureus, the level ofMcl-1was
signi�cantly higher (Figure 2(d)). Cumulatively, these results
clearly showed the dual nature of the effects of S. aureus on
Mcl-1, which involved increased Mcl-1 protein synthesis as
well as increased protein stability.
3.3. e Mcl-1 Expression Correlates with Prevalence and
Severity of S. aureus-Induced Arthritis. S. aureus is the
causative agent in about 60% of nongonococcal bacterial
arthritis cases, a disease characterized among others by
robust in�ux of macrophages and their sustain activation in
joints [15, 16].erefore, we determinedMcl-1 expression in
in�amed joints in the previously establishedmurinemodel of
S. aureus arthritis [17]. To this end DBA1 mice were injected
i.v. with 5 × 107 CFU, a dose causing a low mortality rate
(see Supplementary Figure 1(a) in Supplementary Material
available online at http://dx.doi.org/10.1155/2013/427021).
At day 8 aer injection all animals showed clear symptoms of
arthritis (Supplementary Figure 1(b)). Bacteriological exam-
ination of joints, spleen, and kidneys revealed the abundant
load of S. aureus in 100% of mice (Supplementary Fig-
ure 1(c)). is �nding correlates with in�ammatory response
manifested by IL-6 secretion (Supplementary Figure 1(d))
and splenomegaly (data not shown). Further investigation
of the relationship between both clinical and bacteriological
signs of arthritis and Mcl-1 expression in joints revealed the
signi�cant association (Figures 3(a) and 3(b)).We foundMcl-
1 expression being signi�cantly upregulated in S. aureus-
positive joints (32.83 ± 7.94-fold above the control level) in
comparison to noninfected tissues (4.29 ± 0.82-fold above
the control level, 𝑃𝑃 𝑃 0.001). Furthermore, we also observed
positive association between the Mcl-1 expression level and
bacterial load in joints. is indicates that S. aureus induced
Mcl-1 expression also in vivo in the in�amed tissue.
3.4. Downregulation ofMcl-1 Interferes with S. aureus-Induced
Cytoprotection. Aswe described previously S. aureus protects
infected macrophages, both human and murine, against
induced cell death [7].us, to further determinewhether the
survival of infected macrophages in response to proapoptotic
stimulants was dependent on Mcl-1 synthesis, RNA inter-
ference with siRNA was used to selectively silence MCL1
gene expression. Treatment of cells with an MCL1-speci�c
siRNA, but not a nonspeci�c control siRNA, resulted in
speci�c and e�cient suppression of Mcl-1 protein levels at
24–72 h aer-transfection (data not shown) without effect
on macrophages viability. e infection of macrophages
24 h aer-transfection has not in�uenced the low level of
already silenced protein within 24–48 h aer infection (Fig-
ure 4(a)). e increasing caspase-3 activity (Figure 4(b)) and
a lactate dehydrogenase leaking from macrophages (Figure
4(c)) revealed that the knockdown of MCL1 expression
Mediators of In�ammation 7




























































F 4: Effect of Mcl-1 expression on cytoprotection induced by S. aureus in hMDMs. (a) Human macrophages were treated with an
MCL1 siRNA (siM�L1) or a nonspeci�c siRNA (siNS). At 24 h following transfection macrophages were infected with S. aureus at an
MOI 1 : 50. Aer additional 24 h cells were collected and Mcl-1 expression was detected by immunoblot. Data are representative of three
separate experiments using hMDMs derived from different donors. (b) e increase in caspase-3 activity (RFU/min) induced by STS in
MCL1 knockdownmacrophages infected with S. aureus. Twenty-four hours aer treatment with siRNA, hMDMswere infected with S. aureus
(24 h), followed by treatment with STS at a concentration of 1 𝜇𝜇M for 18 h. e measurement of caspase-3 activity (RFU/min) in cell lysates
was performed using DE�D-AF� as a substrate. e �gure is representative of three experiments, using hMDMs cultures obtained from
different donors. Light bars—STS, dark bars—Sa + STS. Data represent means ± SD. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃; ∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃; ∗∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃. (c) Increased
susceptibility to the cytotoxic effects of staurosporine (STS) in MCL1 knockdown macrophages infected with S. aureus. Twenty-four hours
aer treatment with siRNA, hMDMs were infected with S. aureus (24 h), followed by treatment with STS at a concentration of 1 𝜇𝜇M for 24 h.
Plasma membrane permeabilisation or cell lysis induced in the hMDMs was assessed by measuring LDH activity in the culture medium.
LDH activity in the media of cells treated only with STS was arbitrarily set as 100%. Results were calculated based on data (± SD) from three
separate experiments. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
signi�cantly attenuated the S. aureus-exerted cytoprotection
of cells in a staurosporine-induced cell deathmodel. Our data
also indicates (Supplementary Figure 2) that silencing ofMcl-
1 in S. aureus-infected macrophages partly ablates the cyto-
protection against spontaneous cell death. is observation
con�rmed that Mcl-1 plays an important role in preventing
apoptosis in S. aureus-infected human macrophages.
3.5. S. aureus-Dependent Mcl-1 Expression Is Regulated by
IL-6. IL-6 upregulates Mcl-1 in human myeloma cells [18].
To determine whether IL-6 was also playing a role in S.
aureus-induced Mcl-1 expression in hMDMs, macrophages
were infected with S. aureus, what leads to IL-6 secretion
within 24 h aer infection (Supplement Figure 3). Both high
mRNA and protein Mcl-1 expression observed aer bacteria
phagocytosis (Figures 5(a) and 5(b), resp.) was markedly
reduced upon treatment of cells with IL-6 receptor (R)
neutralising antibodies. Together, these results demonstrated
that S. aureus-inducedMcl-1 expression is partlymediated by
IL-6.
3.6. e NF𝜅𝜅B Pathway Is Involved in IL-6-Dependent Regu-
lation of Mcl-1 Expression Induced by S. aureus. A variety of
intracellular signalling pathways are activated by pathogens.




















































F 5: Mcl-1 expression induced by S. aureus is mediated by IL-6. (a) hMDMs were preincubated with anti-IL6 receptor antibodies
(1 𝜇𝜇g/mL) for 30min and then infected with S. aureus at an MOI of 1 : 50 and/or stimulated with IL-6 (200 ng/mL). At 7 h p.i., RNA was
extracted and relative MCL1 expression was measured by qRT-PCR. Diagram shows the mean values calculated from the results of at least
three independent real-time reactions using hMDMs derived from different donors. Bars represent mean relative expression ± SD. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
(b) hMDMs were preincubated with anti-IL6 receptor (1 𝜇𝜇g/mL) antibodies for 30min and then infected with S. aureusNewman at an MOI
of 1 : 50. e effect of S. aureus on Mcl-1 protein synthesis was measured 20 h aer-infection by immunoblot. Shown is a representative
immunoblot from three separate experiments performed on hMDMs derived from different donors.
Among them, activation of NF𝜅𝜅B has been shown to be
critical for cytoprotection of infected cells [19]. Moreover, S.
aureus is a potent inducer of NF𝜅𝜅B activity as was con�rmed
in infected macrophages by EMSA (Supplement Figure 4).
To determine the effect of inhibition of the NF𝜅𝜅B pathway
on Mcl-1 expression in hMDMs, macrophages were infected
with S. aureus followed by incubation for 6 h with a speci�c
NF𝜅𝜅B-inhibitor, and then the levels of MCL1 were assessed
in comparison to untreated infected cells. As seen in Figure
6(a), inhibition of the NF𝜅𝜅B pathway abrogated the S. aureus-
induced increase in MCL1 gene transcription. is effect
was con�rmed at the protein level as well (Figure 6(b)).
ese results strongly suggested that Mcl-1 expression in
S. aureus-infected cells is dependent on NF𝜅𝜅B. Since IL-6
transcription is upregulated in an NF𝜅𝜅B-dependent manner
[20], we investigated the possibility that NF𝜅𝜅B stimulated
MCL1 expression indirectly, via IL-6. S. aureus-induced
production of IL-6 in infected macrophages was abrogated
by treatment with Bay 11-7095, the NF𝜅𝜅B-speci�c cell-
permeable inhibitor, which indicated that IL-6 production
was absolutely dependent on NF𝜅𝜅B (Figure 6(c)). Taken
together, these �ndings indicate that IL-6-mediated Mcl-1
expression in infected macrophages is regulated through the
NF𝜅𝜅B pathway.
Since we proved that the S. aureus mediated Mcl-1
induction in both human and murine model, therefore, in
all further experiments we routinely use the hMDMs and/or
RAW 264.7 cell line.
3.7. NF𝜅𝜅B and IL-6 Are Required for S. aureus-Induced Inhibi-
tion ofMacrophage Apoptosis. Based on the fact that S. aureus
delayed apoptosis through Mcl-1 upregulation in infected
macrophages we investigated whether NF𝜅𝜅B-dependent
pathways and/or IL-6 were necessary for S. aureus-induced
inhibition of apoptosis. In this experiment we used both
hMDMs and murine macrophage RAW 264.7 cell line, the
latter to verify the results of Mcl-1 induction in mice joints
by S. aureus infection. Preincubation of macrophages with an
NF𝜅𝜅B inhibitor (Bay 11-7095) reversed antiapoptotic effect
(measured by caspase-3 activation) induced by S. aureus
in staurosporine-treated cells (Figure 7(a)). e viability of
hMDMs was also assessed aer blocking IL-6 signalling.
Pretreatment of humanmacrophages with IL-6R neutralising
antibodies partly abolished S. aureus-induced protection
against cell death exerted by staurosporine, but had no effect
on cytoprotection against cycloheximide- (CHX-) mediated
cell death (Figure 7(b)). To determine whether IL-6 acted
in an autocrine manner to prevent cell death induced by
staurosporine, conditioned media from S. aureus-infected
macrophages containing abundant IL-6 (Supplement Figure
3) was added to noninfected macrophages, followed by
treatment of the cells with staurosporine. To con�rm the
role of secreted upon S. aureus infection IL-6 on suppression
of macrophages apoptosis we blocked the action of IL-6
using anti-IL6 receptor (1 𝜇𝜇g/mL) antibodies. Measurement
of caspase-3 activity revealed a signi�cant effect, albeit one
that was weaker than that induced by S. aureus infection, of




































































F 6: NF𝜅𝜅B is required for Mcl-1 expression induced by S. aureus. (a, b) hMDMs were pretreated for 30min with Bay 11-7095 (40 𝜇𝜇M)
followed by S. aureus infection at an MOI of 50. Aer the indicated times, RNA and protein were extracted and Mcl-1 expression levels were
determined by qRT-PCR and immunoblot (a and b, resp.). Data represent the means ± SD from three separate experiments. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃. (c)
e effect of NF𝜅𝜅B inhibition on IL-6 expression was measured by qRT-PCR. Shown are the mean values calculated from the results of �ve
independent real-time reactions using hMDMs derived from different donors. Bars represent mean relative expression ± SD; ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
the conditioned medium on cytoprotection, which can be
partly reversed by IL-6 signalling inhibition (Figure 7(c)).
Cumulatively, these data demonstrate that the induction of
IL-6 production in macrophages upon S. aureus infection is
an important factor in the activation of downstream events
that lead to suppression of the intrinsic apoptotic pathway
through de novo synthesis Mcl-1.
4. Discussion
Results from recent in vitro studies have demonstrated
that macrophages infected with S. aureus are resistant to
apoptosis (both induced and spontaneous), and this apparent
cytoprotective effect is a consequence of the signi�cant
upregulation of antiapoptotic genes, especially those involved
in the mitochondrial pathway, such as MCL1 [7]. Here, we
investigated this phenomenon in more detail and showed for
the �rst time that S. aureus-induced resistance to cell death is
highly dependent onMcl-1 expression since speci�c silencing
of MCL1 abrogated the effect. In this respect, S. aureus
clearly resembles M. tuberculosis or respiratory syncytial
virus (RSV), well-known obligatory intracellular pathogens
that employ a similar strategy [21, 22].
Mcl-1 is a short-lived cytoplasmic protein (half-life of
approximately 3 h) destined for prompt degradation by the
proteasome [23, 24]. is fast proteolytic removal of Mcl-
1 was markedly slowed in S. aureus-infected macrophages.
e level of Mcl-1 rapidly increased within 2 h aer bacterial
infection, reached a maximum at 6 h, and then remained
elevated for up to 24 h. In addition to enhanced MCL1
gene expression [7], this increase in Mcl-1 levels was due
in large part to increased Mcl-1 stability. In contrast to
























































































































F 7:e role ofNF𝜅𝜅B and IL-6 in cytoprotection induced by S. aureus. (a) Inhibition of S. aureus-induced cytoprotection upon treatment
with anNF𝜅𝜅B inhibitorwas assessed bymeasuring caspase-3 activation. RAW264.7macrophageswere pretreated for 30minwithBay 11-7095
(4 𝜇𝜇M) followed by bacterial infection at anMOI of 5 for 2 h. STS was added for an additional 3 h, and then caspase-3 activity wasmeasured in
cell lysates (as described in Section 2). Data represent mean ± SD caspase-3 activity (RFU/min) from three separate experiments. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
(b, c) e in�uence of IL-6 on STS- (1 𝜇𝜇M) or CHX- (10 𝜇𝜇M) induced cytotoxicity in S. aureus-infected macrophages. (b) hMDMs were
preincubated with anti-IL6 receptor antibodies (1 𝜇𝜇g/mL) for 1 h followed by S. aureus infection at an MOI of 1 : 50 for 2. STS or CHX was
added for 6 h, and then permeabilisation of the plasma membrane or cell lysis was determined by measuring LDH activity in conditioned
media. Cell death aer treatment with STS or CHX alone was set as 100%. Diagram shows the mean values calculated from the results of
three independent experiments using hMDMs derived from different donors. Bars represent mean relative expression ± SD; ∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃;
NS: not signi�cant. (c) RAW 264.7 cells were infected with S. aureus (MOI 1 : 5) or stimulated with conditioned medium collected from
infected RAW 264.7 cells 5 h p.i. alone (cmed) or with anti-IL6 receptor (1 𝜇𝜇g/mL) antibodies (cmed + anty-IL6R). At 2 h aer stimulation,
macrophages were treated with STS for another 4 h and then caspase-3 activity wasmeasured. Caspase-3 activation induced by STS alone was
set as 100%. Shown are mean values calculated from the results of three independent experiments. Bars represent mean relative expression ±
SD; ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃; ∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
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control cells, the relative levels of Mcl-1 in infected cells
were only slightly decreased by inhibition of protein trans-
lation. is is consistent with the resistance of S. aureus
infected macrophages to cell death experimentally induced
by cycloheximide.us, apoptosis inhibition inmacrophages
following S. aureus infection involves both enhancement of
MCL1 transcription and the prolonged life-time of Mcl-
1 in infected cells. is underscores the essential role of
antiapoptotic Mcl-1 in S. aureus-induced cytoprotection in
macrophages and argues that hijacking of Mcl-1 function is
essential for survival of infected cells thus facilitating survival
of intracellular invaders.
e con�rmation of Mcl-1 role in staphylococcal infec-
tion was obtained studying S. aureus-induced septic arthri-
tis. Our data clearly shows enhanced Mcl-1 expression in
infected joints. is suggests that also in vivo S. aureus yields
cytoprotection to infected cells establishing a safe haven
impervious to attack by antibacterial forces of the immune
system. Taking into account that the majority of synovial
cells in the cartilage-synovium junction that participate in the
destructive process aremacrophages, the prolonged life-spam
of infected phagocytes may be directly linked to the severity
of septic arthritis lesions. Our hypothesis is corroborated
by both the level of bacterial infection/spreading and the
Mcl-1 expression in peritoneal macrophages isolated from
S. aureus-infected mice, which are higher in comparison to
macrophages from infected animals additionally exposed to
NF𝜅𝜅B or IL-6 signalling inhibitors (data not shown).
IL-6 plays an important role in pathogenesis of septic
arthritis promoting synovitis, manifested by stimulation
of chemokines and adhesion molecules and in�ltration of
in�ammatory cells, such as macrophages and lymphocytes.
IL-6 has been also shown to be essential for Mcl-1 expression
thus promoting accumulation of macrophages [25]. ere-
fore, S. aureus-induced IL-6 secretion could be responsible
for Mcl-1 upregulation in infected macrophages. In keeping
with this, Mcl-1 induction was partly attenuated by specif-
ically blocking the IL-6R, which suggests an autocrine role
of IL-6 in the S. aureus-induced cytoprotection of infected
macrophages through increased expression of Mcl-1. is
effect is regulated by the NF𝜅𝜅B pathway as it is apparent
from the observation that Mcl-1 expression was decreased
upon inhibition of NF𝜅𝜅B. However, it should be underlined
that, since Mcl-1 can be induced by several different sur-
vival and differentiation signals, both on transcriptional and
posttranscriptional levels, the involvement of NF𝜅𝜅B and IL-
6 pathways in this process is a part of the very complex
regulation network.
Interactions between hosts and pathogens vary depend-
ing on the strategies employed by the pathogens to deter
host immunity. erefore, de�ning the defence mechanisms
that are selective for a particular pathogen or, conversely, the
precise virulence strategy of the pathogen is a crucial step in
predicting the outcome of infection. Described here and in
a previous report [7] sustained Mcl-1 expression and cyto-
protection of macrophages by S. aureus following infection
appears to be speci�c for this bacterium, since engulfment
of Gram-negative bacteria or latex beads yielded negligible
effects. Such highly speci�c activation of Mcl-1 expression
could be bene�cial for the host or advantageous for S. aureus.
Pathogen persistence or replication in a protected intracellu-
lar environment and dissemination before infected cells are
removed by Fas-mediated apoptosis argue strongly for the
latter option. A similar strategy is employed by M. tuber-
culosis, an obligatory intracellular pathogen, which employs
a strategy whereby intracellular replication is prolonged
by Mcl-1 upregulation and inhibition of apoptosis, hence
promoting chronic persistence [22]. e opposite mode of
action has been documented for Streptococcus pneumoniae
infection, where initial enhancement of macrophage viability
allows professional phagocytes to eradicate the infection [26].
erefore, based on presented data we propose the
scenario in which intracellular S. aureusmakes macrophages
resistant to apoptosis thus using these mobile cells as the
Trojan horse to disseminate. e follow-up study aimed to
unambiguously verify this attractive hypothesis is in progress
in our laboratory.
5. Conclusions
To sum up, our work describes the mechanism of Mcl-1
induction and its pivotal role in S. aureus-mediated cytopro-
tection of infected macrophages. Moreover, the upregulation
of Mcl-1 in vivo indicates that observed phenomenon plays a
role during staphylococcal infection.
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